Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report

Background IgA vasculitis nephritis (IgAVN) with podocyte injury is a treatment-refractory subtype of IgA vasculitis that often responds poorly to glucocorticoids and is accompanied by persistent proteinuria. New-onset IgAVN during interleukin-17A (IL-17A) inhibitor therapy in patients with ankylosing spondylitis (AS) is extremely rare. Case presentation A 24-year-old, HLA-B27–positive man with axial-predominant AS on long-term secukinumab developed palpable purpura after an influenza virus infection, followed by hematuria and proteinuria. Renal biopsy revealed proliferative necrotizing IgAVN (ISKDC grade III) with diffuse podocyte foot-process effacement. Prednisone 30 mg/day for 6 days did not improve proteinuria (24-h urinary protein increased from 1.28 g to 1.44 g) and axial AS symptoms relapsed. Glucocorticoids were replaced with rituximab (RTX) 500 mg intravenously every 7–10 days for 4 infusions, with concomitant discontinuation of secukinumab. Results Four weeks after the first infusion, peripheral blood CD19+ B cells were completely depleted and 24-h urinary protein decreased to 0.83 g; at 6 months it was 0.06 g and remained negative, with serum albumin normalized. AS remained stable after IL-17A inhibitor withdrawal (BASDAI score of 0). One pulmonary infection occurred during RTX treatment and resolved with anti-infective therapy. Conclusion RTX may be an effective option for IgAVN with podocyte injury and inadequate glucocorticoid response in patients with AS, and may help maintain AS stability after IL-17A inhibitor discontinuation.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.2011766
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report

Yangyang Zhang, Yan Liu, Qi Yu, Yanlang Yang et al.
1 links
Frontiers in Medicine
Renal Diseases and Glomerulopathies
article

Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report

Yangyang Zhang, Yan Liu, Qi Yu, Yanlang Yang, Yiyuan Yuan
article en

Abstract

Background IgA vasculitis nephritis (IgAVN) with podocyte injury is a treatment-refractory subtype of IgA vasculitis that often responds poorly to glucocorticoids and is accompanied by persistent proteinuria. New-onset IgAVN during interleukin-17A (IL-17A) inhibitor therapy in patients with ankylosing spondylitis (AS) is extremely rare. Case presentation A 24-year-old, HLA-B27–positive man with axial-predominant AS on long-term secukinumab developed palpable purpura after an influenza virus infection, followed by hematuria and proteinuria. Renal biopsy revealed proliferative necrotizing IgAVN (ISKDC grade III) with diffuse podocyte foot-process effacement. Prednisone 30 mg/day for 6 days did not improve proteinuria (24-h urinary protein increased from 1.28 g to 1.44 g) and axial AS symptoms relapsed. Glucocorticoids were replaced with rituximab (RTX) 500 mg intravenously every 7–10 days for 4 infusions, with concomitant discontinuation of secukinumab. Results Four weeks after the first infusion, peripheral blood CD19+ B cells were completely depleted and 24-h urinary protein decreased to 0.83 g; at 6 months it was 0.06 g and remained negative, with serum albumin normalized. AS remained stable after IL-17A inhibitor withdrawal (BASDAI score of 0). One pulmonary infection occurred during RTX treatment and resolved with anti-infective therapy. Conclusion RTX may be an effective option for IgAVN with podocyte injury and inadequate glucocorticoid response in patients with AS, and may help maintain AS stability after IL-17A inhibitor discontinuation.

Frontiers in MedicineVol. 13
First Affiliated Hospital of Wannan Medical College (CN)
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon